Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: Secondary analyses from a placebo-controlled randomized trial

被引:36
作者
Pomara, Nunzio
Ott, Brian R.
Peskind, Elaine
Resnick, E. Malca
机构
[1] Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA
[2] NYU, Sch Med, Orangeburg, NY USA
[3] Brown Univ, Sch Med, Providence, RI 02912 USA
[4] Univ Washington, Seattle, WA 98195 USA
[5] Forest Res Inst, Jersey City, NJ USA
关键词
Alzheimer disease; memantine; ADAS-cog;
D O I
10.1097/WAD.0b013e318032cf29
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Memantine, an N-methyl-D-aspartate receptor antagonist, is approved in the United States and Europe for the treatment of moderate to severe Alzheimer disease (AD) and has also been investigated in patients with mild to moderate AD. To characterize the specific cognitive benefits of memantine in patients with mild to moderate AD, a post hoc analysis was conducted of a 24-week randomized, double-blind, placebo-controlled, clinical trial comparing memantine (10 mg twice daily) to placebo. Cognition was assessed using the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) total score, individual items, and aggregated subscales, using a mixed model repeated measures analysis. As assessed by the ADAS-cog total score, participants in the placebo group demonstrated significantly more cognitive decline from baseline than participants treated with memantine at all visits beginning at week 8. Subjects treated with placebo also declined significantly more than individuals in the memantine group on 5 of 11 ADAS-cog individual items: orientation, language, comprehension, word finding, and recall of test instructions. Out of 3 ADAS-cog aggregated item subscales (language, memory, and praxis), outcomes in 2 (language and memory) favored memantine. Consistent with findings from trials conducted in moderate to severe AD patients, this post hoc analysis of a randomized clinical trial suggests that memantine benefits core aspects of language and some aspects of memory in patients with mild to moderate AD.
引用
收藏
页码:60 / 64
页数:5
相关论文
共 14 条
[1]
MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN [J].
FOLSTEIN, MF ;
FOLSTEIN, SE ;
MCHUGH, PR .
JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) :189-198
[2]
KIM SR, 1994, SEX PLANT REPROD, V7, P76, DOI 10.1007/BF00230575
[3]
MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
[4]
CHOLINERGIC SYSTEM AND CONSTRUCTIONAL PRAXIS - A FURTHER STUDY OF PHYSOSTIGMINE IN ALZHEIMERS-DISEASE [J].
MURAMOTO, O ;
SUGISHITA, M ;
ANDO, K .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1984, 47 (05) :485-491
[5]
ASSESSING RESPONSE TO TACRINE USING THE FACTOR-ANALYTIC STRUCTURE OF THE ALZHEIMERS-DISEASE ASSESSMENT SCALE (ADAS) COGNITIVE SUBSCALE [J].
OLIN, JT ;
SCHNEIDER, LS .
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 1995, 10 (09) :753-756
[6]
Choline acetyltransferase activity and cognitive domain scores of Alzheimer's patients [J].
Pappas, BA ;
Bayley, PJ ;
Bui, BK ;
Hansen, LA ;
Thal, LJ .
NEUROBIOLOGY OF AGING, 2000, 21 (01) :11-17
[7]
Memantine treatment in mild to moderate Alzheimer disease: A 24-week randomized, controlled trial [J].
Peskind, Elaine R. ;
Potkin, Steven G. ;
Pomara, Nunzio ;
Ott, Brian R. ;
Graham, Stephen M. ;
Olin, Jason T. ;
McDonald, Scott .
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2006, 14 (08) :704-715
[8]
Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease [J].
Raskind, MA ;
Sadowsky, CH ;
Sigmund, WR ;
Beitler, PJ ;
Auster, SB .
ARCHIVES OF NEUROLOGY, 1997, 54 (07) :836-840
[9]
PATHOLOGICAL VERIFICATION OF ISCHEMIC SCORE IN DIFFERENTIATION OF DEMENTIAS [J].
ROSEN, WG ;
TERRY, RD ;
FULD, PA ;
KATZMAN, R ;
PECK, A .
ANNALS OF NEUROLOGY, 1980, 7 (05) :486-488
[10]
ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356